WO2001051638A3 - Enzymes de metabolisation de medicaments - Google Patents

Enzymes de metabolisation de medicaments Download PDF

Info

Publication number
WO2001051638A3
WO2001051638A3 PCT/US2001/001174 US0101174W WO0151638A3 WO 2001051638 A3 WO2001051638 A3 WO 2001051638A3 US 0101174 W US0101174 W US 0101174W WO 0151638 A3 WO0151638 A3 WO 0151638A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolizing enzymes
drug metabolizing
dme
provides
polynucleotides
Prior art date
Application number
PCT/US2001/001174
Other languages
English (en)
Other versions
WO2001051638A2 (fr
Inventor
Junming Yang
Mariah R Baughn
Neil Burford
Janice Au-Young
Dyung Aina M Lu
Roopa Reddy
Huijun Z Ring
Jennifer L Hillman
Henry Yue
Yalda Azimzai
Monique G Yao
Ameena R Gandhi
Danniel B Nguyen
Y Tom Tang
Preeti Lal
Olga Bandman
Original Assignee
Incyte Genomics Inc
Junming Yang
Mariah R Baughn
Neil Burford
Au Young Janice
Dyung Aina M Lu
Roopa Reddy
Huijun Z Ring
Jennifer L Hillman
Henry Yue
Yalda Azimzai
Monique G Yao
Ameena R Gandhi
Danniel B Nguyen
Y Tom Tang
Preeti Lal
Olga Bandman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Junming Yang, Mariah R Baughn, Neil Burford, Au Young Janice, Dyung Aina M Lu, Roopa Reddy, Huijun Z Ring, Jennifer L Hillman, Henry Yue, Yalda Azimzai, Monique G Yao, Ameena R Gandhi, Danniel B Nguyen, Y Tom Tang, Preeti Lal, Olga Bandman filed Critical Incyte Genomics Inc
Priority to JP2001551212A priority Critical patent/JP2004500816A/ja
Priority to AU2001227900A priority patent/AU2001227900A1/en
Priority to US10/181,108 priority patent/US20040086854A1/en
Priority to CA002397340A priority patent/CA2397340A1/fr
Priority to EP01902057A priority patent/EP1254235A2/fr
Publication of WO2001051638A2 publication Critical patent/WO2001051638A2/fr
Publication of WO2001051638A3 publication Critical patent/WO2001051638A3/fr
Priority to US11/079,743 priority patent/US20050181415A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01001—Alcohol dehydrogenase (1.1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Enzymes de métabolisation de médicaments (DME) et polynucléotides identifiant et codant ces DME. L'invention concerne aussi des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes, de même que des procédés pour diagnostiquer, traiter ou prévenir des troubles associés avec une expression aberrante de DME.
PCT/US2001/001174 2000-01-14 2001-01-12 Enzymes de metabolisation de medicaments WO2001051638A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001551212A JP2004500816A (ja) 2000-01-14 2001-01-12 薬剤代謝酵素
AU2001227900A AU2001227900A1 (en) 2000-01-14 2001-01-12 Drug metabolizing enzymes
US10/181,108 US20040086854A1 (en) 2001-01-12 2001-01-12 Drug metabolizing enzymes
CA002397340A CA2397340A1 (fr) 2000-01-14 2001-01-12 Enzymes de metabolisation de medicaments
EP01902057A EP1254235A2 (fr) 2000-01-14 2001-01-12 Enzymes de metabolisation de medicaments
US11/079,743 US20050181415A1 (en) 2000-01-14 2005-03-14 Drug metabolizing enzymes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17613900P 2000-01-14 2000-01-14
US60/176,139 2000-01-14
US17744300P 2000-01-21 2000-01-21
US60/177,443 2000-01-21
US17857400P 2000-01-28 2000-01-28
US60/178,574 2000-01-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/079,743 Division US20050181415A1 (en) 2000-01-14 2005-03-14 Drug metabolizing enzymes

Publications (2)

Publication Number Publication Date
WO2001051638A2 WO2001051638A2 (fr) 2001-07-19
WO2001051638A3 true WO2001051638A3 (fr) 2002-03-21

Family

ID=27390641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001174 WO2001051638A2 (fr) 2000-01-14 2001-01-12 Enzymes de metabolisation de medicaments

Country Status (5)

Country Link
EP (1) EP1254235A2 (fr)
JP (1) JP2004500816A (fr)
AU (1) AU2001227900A1 (fr)
CA (1) CA2397340A1 (fr)
WO (1) WO2001051638A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369969A1 (fr) * 1999-04-15 2000-10-26 Curagen Corporation Procede d'identification d'agents toxiques au moyen d'une expression genetique differentielle
JP2003518365A (ja) * 1999-07-02 2003-06-10 キュラジェン コーポレイション 示差的遺伝子発現を使用する毒性因子の同定方法
US20040142361A1 (en) * 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20020146727A1 (en) * 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
US6436684B1 (en) * 2000-03-27 2002-08-20 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en) 2000-10-20 2005-09-27 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2003052087A2 (fr) * 2001-12-14 2003-06-26 Bayer Healthcare Ag Regulation de la deshydrogenase/reductase humaine a chaine courte
JPWO2003052103A1 (ja) * 2001-12-17 2005-04-28 独立行政法人産業技術総合研究所 膜結合型グルタチオン非特異的プロスタグランジンｅ合成酵素
WO2003093826A2 (fr) * 2002-04-29 2003-11-13 Clinigenetics Dosages permettant d'identifier des molecules hypocholesterolemiantes
ATE398974T1 (de) 2002-11-27 2008-07-15 Medical Device Innovations Ltd Coaxiale gewebeablationsprobe und verfahren zum herstellen eines symmetriergliedes dafür
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463395A1 (fr) * 1990-06-22 1992-01-02 F. Hoffmann-La Roche Ag Dépistage des métabolisateurs faibles de drogues
EP0905232A1 (fr) * 1996-12-12 1999-03-31 Kirin Beer Kabushiki Kaisha NOUVELLE Beta 1-4 N-ACETYLGLUCOSAMINYLTRANSFERASE ET GENE LA CODANT
WO2000006698A1 (fr) * 1998-07-30 2000-02-10 Human Genome Sciences, Inc. 98 proteines humaines secretees

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463395A1 (fr) * 1990-06-22 1992-01-02 F. Hoffmann-La Roche Ag Dépistage des métabolisateurs faibles de drogues
EP0905232A1 (fr) * 1996-12-12 1999-03-31 Kirin Beer Kabushiki Kaisha NOUVELLE Beta 1-4 N-ACETYLGLUCOSAMINYLTRANSFERASE ET GENE LA CODANT
WO2000006698A1 (fr) * 1998-07-30 2000-02-10 Human Genome Sciences, Inc. 98 proteines humaines secretees

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GASDASKA ET AL.: "Cloning, sequencing and functional expression of a novel human thioredoxin reductase", FEBS LETTERS, vol. 442, 1999, pages 105 - 111, XP002924546 *
GASDASKA ET AL.: "Thioredoxin reductase", SWISSPROT SEQUENCE DATA BASE, 1 May 1999 (1999-05-01), XP002169070 *
HILLIER ET AL.: "WashU-NCI human EST project", EMBL SEQUENCE DATABASE, 29 June 1999 (1999-06-29), HEIDELBERG DE, XP002169067 *
KIMURA ET AL.: "Cytochrome P450 2D6 (EC 1.14.14.1) (CYPIID6) (P450-DB1) (Debrisoquine 4-hydroxylase)", SWISSPROT SEQUENCE DATA BASE, 1 July 1989 (1989-07-01), XP002169069 *
KIMURA ET AL.: "The human debrosoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene", AM. J. HUM. GENET., vol. 45, 1989, pages 889 - 904, XP000570035 *
LIN: "CGI-82 protein", SWISSPROT SEQUENCE DATA BASE, 1 November 1999 (1999-11-01), XP002169068 *
NCI-CGAP: "qa48b12.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:1689983 3', mRNA sequence", EMBL SEQUENCE DATABASE, 8 September 1998 (1998-09-08), HEIDELBERG DE, XP002169066 *

Also Published As

Publication number Publication date
AU2001227900A1 (en) 2001-07-24
CA2397340A1 (fr) 2001-07-19
EP1254235A2 (fr) 2002-11-06
WO2001051638A2 (fr) 2001-07-19
JP2004500816A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
WO2001098468A3 (fr) Proteases
WO2003052075A3 (fr) Enzymes
WO2001096547A3 (fr) Kinases humaines
WO2001051638A3 (fr) Enzymes de metabolisation de medicaments
WO2002018557A3 (fr) Kinases humaines
WO2001060991A3 (fr) Kinases humaines
WO2001090334A3 (fr) Enzymes de metabolisation de medicaments
WO2002004612A3 (fr) Enzymes metabolisant les medicaments
WO2001072777A3 (fr) Facteurs de transcription
WO2001046397A3 (fr) Kinases humaines
WO2003042357A3 (fr) Enzymes
WO2001098471A8 (fr) Phosphodiesterases
WO2002026950A3 (fr) Transferases
WO2001096546A3 (fr) Proteine-phosphatases
WO2001085942A3 (fr) Proteines associees au cytosquelette
WO2001053468A3 (fr) Enzymes du metabolisme lipidique (lme)
WO2002010363A3 (fr) Proteines phosphatases
WO2000042201A3 (fr) Peptidases humaines
WO2001079468A3 (fr) Enzymes metabolisant les medicaments
WO2001059127A3 (fr) Enzymes metabolisant les medicaments
WO2001071004A3 (fr) Proteases
WO2002012467A3 (fr) Enzymes métabolisant les médicaments
WO2001081555A3 (fr) Kinases humaines
WO2002033099A3 (fr) Kinases humaines
WO2001055358A3 (fr) Phosphodiesterases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10181108

Country of ref document: US

Ref document number: 2397340

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 551212

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001902057

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001902057

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001902057

Country of ref document: EP